Centessa Pharmaceuticals’ SerpinPC Gains Orphan Drug Designation

September 16, 2022

The FDA has given Centessa Pharmaceuticals’ SerpinPC Orphan Drug designation for the treatment of patients with hemophilia B.

SerpinPC is a biological drug candidate based on the serpin family of proteins. It’s designed to allow more thrombin to be generated by inhibiting activated protein C. The aim is to provide a rebalance of coagulation, said the company.

Centessa plans to make SerpinPC a subcutaneous option to prevent and reduce bleeds without the risk of thrombosis in patients with hemophilia B.

The company said it will initiate registrational studies for SerpinPC later this year.

View today's stories